Table 2.
Results of univariate survival analysis
| Characteristic | Baseline model (N = 323) |
Chemotherapy response-based model (N = 233) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Gender (female vs male) | 1.45 | 1.10–1.92 | 0.008 | 1.49 | 1.09–2.05 | 0.011 |
| Age (≤56 vs > 56) | 1.01 | 1.00–1.03 | 0.012 | 1.22 | 0.90–1.66 | 0.199 |
| KPS (70 ~ 80 vs 90 ~ 100) | 0.57 | 0.43–0.77 | < 0.001 | 0.45 | 0.33–0.63 | < 0.001 |
| Smoke (No vs Yes) | 1.32 | 1.00–1.74 | 0.047 | 1.41 | 1.03–1.94 | 0.034 |
| Ascites (No vs Yes) | 1.46 | 1.08–1.96 | 0.012 | 1.54 | 1.11–2.16 | 0.011 |
| Baseline WBC (≤ 6.39 vs > 6.39) | 1.63 | 1.25–2.13 | < 0.001 | 1.41 | 1.04–1.91 | 0.027 |
| Baseline N (≤ 0.665 vs > 0.665) | 1.60 | 1.23–2.09 | 0.001 | 1.68 | 1.24–2.29 | 0.001 |
| Baseline LDH (≤159 vs > 159) | 1.38 | 1.06–1.80 | 0.018 | 1.14 | 0.84–1.54 | 0.402 |
| Baseline TB (≤11.4 vs>11.4) | 1.45 | 1.11–1.89 | 0.006 | 1.43 | 1.06–1.94 | 0.021 |
| Baseline Alb (≤ 40.5 vs > 40.5) | 0.76 | 0.58–1.00 | 0.049 | 0.81 | 0.59–1.09 | 0.166 |
| Baseline CEA (≤7.32 vs > 7.32) | 1.47 | 1.13–1.92 | 0.005 | 1.44 | 1.06–1.95 | 0.019 |
| Baseline CA 19–9 (≤1453 vs > 1453) | 1.81 | 1.38–2.37 | < 0.001 | 1.72 | 1.26–2.34 | 0.001 |
| Change in CEA level at week 6 | NI | |||||
| Decrease | Ref | |||||
| No change or increase | 1.39 | 1.02–1.91 | 0.039 | |||
| Change in CA19–9 level at week 6 | NI | |||||
| Decrease | Ref | |||||
| No change or increase | 1.69 | 1.23–2.31 | 0.001 | |||
| Albumin at week 6 (≤39.0 vs>39.0) | NI | 0.67 | 0.49–0.91 | 0.010 | ||
| TB at week 6 (≤11.3 vs>11.3) | NI | 1.36 | 1.01–1.85 | 0.047 | ||
| CEA at week 6 (≤7.97 vs>7.97) | NI | 1.58 | 1.17–2.14 | 0.003 | ||
| CA 19–9 at week 6 (≤790.7 vs>790.7) | NI | 1.99 | 1.46–2.73 | < 0.001 | ||
| Initial response to chemotherapy | NI | |||||
| Non-PD | Ref | |||||
| PD | 3.07 | 2.17–4.35 | < 0.001 | |||